Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

 Antiproteinuric Effect of Sparsentanin Focal Segmental Glomerulosclerosis (FSGS) in the Ongoing 156-Week DUPLEX Open-Label Extension (OLE)

Page 1 / 1 100%
Loading...